A 3-Part Phase 1 Study to Investigate the Absolute Oral Bioavailability and Absorption, Metabolism, and Excretion of 14C-Unesbulin in Patients With Advanced Solid Tumor

2022-502118-10-00 Protocol PTC596-AME-101-AST Human pharmacology (Phase I) - Other Ended

Start 27 Oct 2023 · End 11 Jan 2024 · Status Ended · 1 EU/EEA countries · 2 sites · Protocol PTC596-AME-101-AST

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 12
Countries 1
Sites 2

Solid tumors

Key facts

Sponsor
PTC Therapeutics Inc.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
27 Oct 2023 → 11 Jan 2024
Decision date (initial)
2023-04-17
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2022-502118-10-00
WHO UTN
U1111-1285-5565

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Solid tumors

VersionLevelCodeTermSystem organ class
21.0 LLT 10049280 Solid tumour 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

PTC Therapeutics Inc.

Sponsor organisation
PTC Therapeutics Inc.
Address
100 Corporate Court
City
South Plainfield
Postcode
07080-2400
Country
United States

Scientific contact point

Organisation
PTC Therapeutics Inc.
Contact name
Medical Information, PTC Therapeutics International Limited

Public contact point

Organisation
PTC Therapeutics Inc.
Contact name
Medical Information, PTC Therapeutics International Limited

Locations

1 EU/EEA country · 2 investigational sites

By country

CountryMS statusPlanned subjectsSites
Hungary Ended 12 2
Rest of world 0

Investigational sites

Hungary

2 sites · Ended
Pharmaceutical Research Associates Magyarorszag
PRA Klinikai Farmakológiai Vizsgálóhely, Rottenbiller Utca 13, 1077, Budapest
Central Hospital Of Northern Pest Military Hospital
Onkológiai Osztály, Podmaniczky Utca 109, 1062, Budapest VI

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Hungary 2023-10-27 2023-11-10

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2023-01-09 Hungary Acceptable
2023-04-14
2023-04-17
2 SUBSTANTIAL MODIFICATION SM-2 2023-08-24 Hungary Acceptable
2023-09-28
2023-10-05